HRTS Among Its Peers
End-of-day Nov 19, 2026 · 0 ETFs by 5Y
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −1.5% | −4.7% | −0.9% | −3.6% | +5.3% | +8.6% | — | — | — | +43.6% |
| S&P 500 · VOO | −2.0% | −5.5% | −7.4% | −6.3% | +5.8% | +9.7% | +65.8% | +65.5% | +290.0% | — |
$126 of every $1,000 in HRTS is Eli
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | LLYELI Lilly | Healthcare | 12.63% | $1,263.05 | 5,107 | $7.1M |
| 2 | TMOThermo Fisher Scientific | Healthcare | 5.43% | $542.82 | 4,381 | $3.0M |
| 3 | RHHBYRoche AG | Healthcare | 4.39% | $438.86 | 41K | $2.5M |
| 4 | MRKMerck | Healthcare | 4.06% | $405.63 | 16K | $2.3M |
| 5 | BBIOBridgebio Pharma | Healthcare | 3.80% | $380.17 | 27K | $2.1M |
| 6 | KODKodiak Sciences | Healthcare | 3.78% | $378.08 | 22K | $2.1M |
| 7 | GILDGilead Sciences | Healthcare | 3.52% | $351.92 | 12K | $2.0M |
| 8 | DHRDanaher | Healthcare | 3.15% | $314.97 | 7,704 | $1.8M |
| 9 | RVMDRevolution Medicines | Healthcare | 3.05% | $304.83 | 11K | $1.7M |
| 10 | NOVO-B.CONovo Nordisk A/S | Healthcare | 2.99% | $299.00 | 42K | $1.7M |
| 11 | AZN.LAstrazeneca | Healthcare | 2.94% | $293.93 | 9,157 | $1.6M |
| 12 | ABTAbbott Laboratories | Healthcare | 2.90% | $289.60 | 15K | $1.6M |
| 13 | JNJJohnson & Johnson | Healthcare | 2.85% | $285.38 | 5,851 | $1.6M |
| 14 | NOVN.SWNovartis AG | Healthcare | 2.84% | $283.77 | 10K | $1.6M |
| 15 | VRTXVertex Pharmaceuticals | Healthcare | 2.67% | $267.31 | 2,786 | $1.5M |
HRTS has no close peers in our data yet: […]
No peers with a full year of prices to rank against yet.
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | LLY | ELI Lilly & | 12.63% |
| 2 | TMO | Thermo Fisher Scientific | 5.43% |
| 3 | RHHBY | Roche AG | 4.39% |
| 4 | MRK | Merck & | 4.06% |
| 5 | BBIO | Bridgebio Pharma | 3.80% |
| 6 | KOD | Kodiak Sciences | 3.78% |
| 7 | GILD | Gilead Sciences | 3.52% |
| 8 | DHR | Danaher | 3.15% |
| 9 | RVMD | Revolution Medicines | 3.05% |
| 10 | NOVO-B.CO | Novo Nordisk A/S | 2.99% |
| Fund | Sharpe | Sortino | Volatility | Max DD | Beta | Fee / $10k |
|---|---|---|---|---|---|---|
| HRTS | 0.34 | 0.54 | 17.4% | −11.0% | 0.50 | $99 |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 10, 2025 | Dec 11, 2025 | $0.47 |
| Dec 11, 2024 | Dec 12, 2024 | $0.47 |